ArticleJournal of neurology2024
Real-World experience with efgartigimod in patients with myasthenia gravis.
Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis.European journal of medical research · 2025Pooled it
- A Prospective Clinical Trial of Efgartigimod for New-Onset Generalized Myasthenia Gravis.Current neuropharmacology · 2026Trial
- ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis.Annals of clinical and translational neurology · 2025Trial
- Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper.European journal of neurology · 2026Article
- Clinical Course After a Single Cycle of Rozanolixizumab in Generalized Late-Onset Myasthenia Gravis.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Functional Profiling of Acetylcholine Receptor Antibodies Informs Therapeutic Outcome of FcRn Inhibitor Therapy in Myasthenia Gravis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA.Neurology and therapy · 2026Article
- Clinical Impact of High-Dose Corticosteroids on Healthcare Resource Utilization and Steroid-Related Complications in Patients with Myasthenia Gravis in Japan.Neurology and therapy · 2026Article
- Real-world experience with efgartigimod in generalized myasthenia gravis: a single-center retrospective study in China.Frontiers in immunology · 2026Article
- Investigating the Risk Factors for Medication Nonadherence in Myasthenia Gravis Patients: Establishing a Nomogram Model.Patient preference and adherence · 2026Article
- Assessing efgartigimod dosing patterns and Myasthenia Gravis Activities of Daily Living outcomes in clinical practice: results from a large patient support program database.Frontiers in neurology · 2026Article
- Case report: Efgartigimod combined with intravenous methylprednisolone in a case of co-occurrence of unexplained myasthenia gravis, inflammatory myopathy, and fulminant myocarditis.Frontiers in immunology · 2026Article
- The effect of FcRn inhibition on overlapping autoimmune comorbidity in AChR-seropositive generalized myasthenia gravis.Frontiers in neurology · 2026Article
- Efgartigimod-alfa therapy in acetylcholine receptor antibody myasthenia gravis: Romanian experience.Frontiers in neurology · 2026Article
- Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study.Journal of neurology · 2025Observational
- Clinicopathological profiling and prognosis of idiopathic inflammatory myopathy overlapping with myasthenia gravis: a retrospective cohort study.Journal of neurology · 2025Article
- C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis.Journal of neurology, neurosurgery, and psychiatry · 2025Observational
- Individualized Dosing of Efgartigimod in Patients With Generalized Myasthenia Gravis: Clinical Experience at a Single Center.Muscle & nerve · 2025Article
- New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recommendations for the treatment of myasthenia gravis (MG) have been difficult to develop because of limited evidence from large randomized controlled trials. New drugs and treatment approaches have recently been shown to be effective in phase 3 studies in seropositive generalized (g) MG. One such drug is efgartigimod, a human-Fc-fragment of IgG1, with a high affinity for the endosomal FcRn. We conducted a multicenter study to evaluate the real-world clinical and safety effects of efgartigimod in 22 gMG patients. We evaluated the strategies for the timing of re-treatment with it. The participants received a total of 59 efgartigimod -treatment cycles. The median number of cycles was 2 (range 1-6). Twenty patients (86.3%) improved by at least 2 MG-ADL points after the first treatment cycle. The median MG-ADL score at baseline was 6.5 (range: 3-17) and 2.5 (range: 0-9) post-treatment (p < 0.001). A consistent improvement of at least 2 points in the MG-ADL score after each cycle occurs in 18 patients. The effect duration of the treatment was usually between 4 and 12 weeks. Two major clinical patterns of treatment response were found. Treatment with efgartigimod was also associated with significant reductions of prednisone doses Overall, the treatment was safe and associated with only minor adverse events. The single fatality was apparently due tosevere respiratory failure. We found that efgartigimod is clinically effective, may be used as a steroid sparing agent and is generally safe for gMG patients. We recommend a personalized preventive treatment approach until clinical stabilization, followed by discontinuation and periodic evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.